Differential effects of antipsychotic and glutamatergic agents on the phMRI response to phencyclidine

Neuropsychopharmacology

Volumn 33, Issue 7, 2008, Pages 1690-1703

  Gozzi, Alessandro ^a   Large, Charles H ^a   Schwarz, Adam ^a   Bertani, Simone ^a   Crestan, Valerio ^a   Bifone, Angelo ^a  

^a GSK   (Italy)

Author keywords

Clozapine; fMRI; Lamotrigine; LY363740; Phencyclidine; Raclopride

Indexed keywords

ANTICONVULSIVE AGENT; CLOZAPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; EGLUMETAD; LAMOTRIGINE; NEUROLEPTIC AGENT; PHENCYCLIDINE; RACLOPRIDE;

ARTICLE; ATTENUATION; BLOOD VOLUME; BRAIN CIRCULATION; BRAIN CORTEX; BRAIN MAPPING; BRAIN REGION; CEREBRAL BLOOD VOLUME; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; HIPPOCAMPUS; NEUROTRANSMISSION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; THALAMUS;

ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; BRAIN MAPPING; DRUG INTERACTIONS; EXCITATORY AMINO ACID AGENTS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; OXYGEN; PHENCYCLIDINE; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY;

EID: 43649089662     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301547     Document Type: Article

References (113)

1. Adams B, Moghaddam B (1998). Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J Neurosci 18: 5545-5554.
2. Adler CM, Malhotra AK, Elman I, Goldberg T, Egan M, Pickar D et al (1999). Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am J Psychiatry 156: 1646-1649.
3. Aghajanian GK, Marek GJ (1999). Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release. Brain Res 825: 161-171.
4. Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A et al (2000). Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry 57: 270-276.
5. Bakshi VP, Swerdlow NR, Geyer MA (1994). Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J Pharmacol Exp Ther 271: 787-794.
6. Battaglia G, Monn JA, Schoepp DD (1997). In vivo inhibition of veratridine-evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740 in rats. Neurosci Lett 229: 161-164.
7. Boxerman JL, Hamberg LM, Rosen BR, Weisskoff RM (1995). MR contrast due to intravascular magnetic susceptibility perturbations. Magn Reson Med 34: 555-566.
8. Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A et al (1994). Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 151: 20-26.
9. Brody SA, Geyer MA, Large CH (2003). Lamotrigine prevents ketamine but not amphetamine-induced deficits in prepulse inhibition in mice. Psychopharmacology (Berl) 169: 240-246.
10. Capogna M (2004). Distinct properties of presynaptic group II and III metabotropic glutamate receptor-mediated inhibition of perforant pathway-CA1 EPSCs. Eur J Neurosci 19: 2847-2858.
11. Carlsson A, Waters N, Carlsson ML (1999). Neurotransmitter interactions in schizophrenia - therapeutic implications. Biol Psychiatry 46: 1388-1395.
12. Cartmell J, Monn JA, Schoepp DD (1999). The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats. J Pharmacol Exp Ther 291: 161-170.
13. Cartmell J, Schoepp DD (2000). Regulation of neurotransmitter release by metabotropic glutamate receptors. J Neurochem 75: 889-907.
14. Cavazzuti M, Porro CA, Biral GP, Benassi C, Barbieri GC (1987). Ketamine effects on local cerebral blood flow and metabolism in the rat. J Cereb Blood Flow Metab 7: 806-811.
15. Clinton SM, Meador-Woodruff JH (2004). Thalamic dysfunction in schizophrenia: neurochemical, neuropathological, and in vivo imaging abnormalities. Schizophr Res 69: 237-253.
16. Corbett R, Camacho F, Woods AT, Kerman LL, Fishkin RJ, Brooks K et al (1995). Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacology (Berl) 120: 67-74.
17. Daly DA, Moghaddam B (1993). Actions of clozapine and haloperidol on the extracellular levels of excitatory amino acids in the prefrontal cortex and striatum of conscious rats. Neurosci Lett 152: 61-64.
18. Dean B, Pavey G, Thomas D, Scarr E (2006). Cortical serotonin7, 1D and 1F receptors: effects of schizophrenia, suicide and antipsychotic drug treatment. Schizophr Res 88: 265-274.
19. Duncan GE, Leipzig JN, Mailman RB, Lieberman JA (1998a). Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation. Brain Res 812: 65-75.
20. Duncan GE, Miyamoto S, Leipzig JN, Lieberman JA (1999a). Comparison of brain metabolic activity patterns induced by ketamine, MK-801 and amphetamine in rats: support for NMDA receptor involvement in responses to subanesthetic dose of ketamine. Brain Res 843: 171-183.
21. Duncan GE, Miyamoto S, Leipzig JN, Lieberman JA (1999b). Comparison of brain metabolic activity patterns induced by ketamine, MK-801 and amphetamine in rats: support for NMDA receptor involvement in responses to subanesthetic dose of ketamine. Brain Res 843: 171-183.
22. Duncan GE, Miyamoto S, Leipzig JN, Lieberman JA (1999c). Comparison of brain metabolic activity patterns induced by ketamine, MK-801 and amphetamine in rats: support for NMDA receptor involvement in responses to subanesthetic dose of ketamine. Brain Res 843: 171-183.
23. Duncan GE, Miyamoto S, Leipzig JN, Lieberman JA (1999d). Comparison of brain metabolic activity patterns induced by ketamine, MK-801 and amphetamine in rats: support for NMDA receptor involvement in responses to subanesthetic dose of ketamine. Brain Res 843: 171-183.
24. Duncan GE, Miyamoto S, Leipzig JN, Lieberman JA (2000). Comparison of the effects of clozapine, risperidone, and olanzapine on ketamine-induced alterations in regional brain metabolism. J Pharmacol Exp Ther 293: 8-14.
25. Duncan GE, Moy SS, Knapp DJ, Mueller RA, Breese GR (1998b). Metabolic mapping of the rat brain after subanesthetic doses of ketamine: potential relevance to schizophrenia. Brain Res 787: 181-190.
26. East SZ, Burnet PWJ, Kerwin RW, Harrison PJ (2002). An RT-PCR study of 5-HT6 and 5-HT7 receptor mRNAs in the hippocampal formation and prefrontal cortex in schizophrenia. Schizophr Res 57: 15-26.
27. Farber NB (2003). The NMDA receptor hypofunction model of psychosis. Ann NY Acad Sci 1003: 119-130.
28. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G (1992). Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49: 538-544.
29. Ferris P, Seward E, Dawson GR (2001). Interactions between LY354740, a Group II metabotropic agonist and the GABAA-benzodiazepine receptor complex in the rat elevated plus-maze. J Psychopharmacol 15: 76-82.
30. Flores-Hernandez J, Cepeda C, Hernandez-Echeagaray E, Calvert CR, Jokel ES, Fienberg AA et al (2002). Dopamine enhancement of NMDA currents in dissociated medium-sized striatal neurons: role of D1 receptors and DARPP-32. J Neurophysiol 88: 3010-3020.
31. Friston KJ, Jezzard P, Turner R (1994). Analysis of functional MRI time-series. Hum Brain Mapp 1: 153-171.
32. Gaisler-Salomon I, Weiner I (2003). Systemic administration of MK-801 produces an abnormally persistent latent inhibition which is reversed by clozapine but not haloperidol. Psychopharmacology V166: 333-342.
33. Gozzi A, Ceolin L, Schwarz AJ, Reese T, Bertani S, Bifone A (2007a). A multimodality investigation of cerebral haemodynamics and autoregulation in phMRI. Magn Reson Imaging 25: 826-833.
34. Gozzi A, Schwarz AJ, Reese T, Bertani S, Crestan V, Bifone A (2005). Region-specific effects of nicotine on brain activity: a pharmacological MRI study in the drug-naïve rat. Neuropsychopharmacology 31: 1690-1703.
35. Gozzi A, Schwarz AJ, Reese T, Crestan V, Bifone A (2007b). Drug-anaesthetic interaction in pharmacological MRI: the case of the psychotogenic agent phencyclidine, Book of abstracts: 15th Annual Meeting of the International Society of Magnetic Resonance in Medicine: P2000.
36. Greene R (2001). Circuit analysis of NMDAR hypofunction in the hippocampus, in vitro, and psychosis of schizophrenia. Hippocampus 11: 569-577.
37. Heidmann DEA, Szot P, Kohen R, Hamblin MW (1998). Function and distribution of three rat 5-hydroxytryptamine7 (5-HT7) receptor isoforms produced by alternative splicing. Neuropharmacology 37: 1621-1632.
38. Hennig J, Nauerth A, Friedburg H (1986). RARE imaging: a fast imaging method for clinical MR. Magn Reson Med 3: 823-833.
39. Hertel P, Mathe JM, Nomikos GG, Iurlo M, Mathe AA, Svensson TH (1995). Effects of d-amphetamine and phencyclidine on behavior and extracellular concentrations of neurotensin and dopamine in the ventral striatum and the medial prefrontal cortex of the rat. Behav Brain Res 72: 103-114.
40. Holcomb HH, Lahti AC, Medoff DR, Cullen T, Tamminga CA (2005). Effects of noncompetitive NMDA receptor blockade on anterior cingulate cerebral blood flow in volunteers with schizophrenia. Neuropsychopharmacology 30: 2275-2282.
41. Homayoun H, Jackson ME, Moghaddam B (2005). Activation of metabotropic glutamate 2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake rats. J Neurophysiol 93: 1989-2001.
42. Idris NF, Repeto P, Neill JC, Large CH (2005). Investigation of the effects of lamotrigine and clozapine in improving reversal-learning impairments induced by acute phencyclidine and D-amphetamine in the rat. Psychopharmacology (Berl) 179: 336-348.
43. Ikeda M, Iwata N, Kitajima T, Suzuki T, Yamanouchi Y, Kinoshita Y et al (2006). Positive association of the serotonin 5-HT7 receptor gene with schizophrenia in a Japanese population. Neuropsychopharmacology 31: 866-871.
44. Jackson ME, Homayoun H, Moghaddam B (2004). NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex. Proc Natl Acad Sci USA 101: 8467-8472.
45. Javitt DC, Duncan L, Balla A, Sershen H (2005). Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action. Mol Psychiatry 10: 275-287.
46. Javitt DC, Zukin SR (1991). Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148: 1301-1308.
47. Jodo E, Suzuki Y, Katayama T, Hoshino KY, Takeuchi S, Niwa SI et al (2005). Activation of medial prefrontal cortex by phencyclidine is mediated via a hippocampo-prefrontal pathway. Cereb Cortex 15: 663-669.
48. Kane J, Honigfeld G, Singer J, Meltzer H (1988). Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45: 789-796.
49. Kapur S, VanderSpek SC, Brownlee BA, Nobrega JN (2003). Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 305: 625-631.
50. Kapur S, Zipursky RB, Remington G (1999). Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 156: 286-293.
51. Kilbride J, Huang LQ, Rowan MJ, Anwyl R (1998). Presynaptic inhibitory action of the group II metabotropic glutamate receptor agonists, LY354740 and DCG-IV. Eur J Pharmacol 356: 149-157.
52. Kircher TT, Thienel R (2005). Functional brain imaging of symptoms and cognition in schizophrenia. Prog Brain Res 150: 299-308.
53. Kohler C, Hall H, Ogren SO, Gawell L (1985). Specific in vitro and in vivo binding of 3H-raclopride a potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain. Biochem Pharmacol 34: 2251-2259.
54. Kristiansen LV, Huerta I, Beneyto M, Meador-Woodruff JH (2007). NMDA receptors and schizophrenia. Curr Opin Pharmacol 7: 48-55.
55. Krystal JH, Abi-Saab W, Perry E, D'Souza DC, Liu N, Gueorguieva R et al (2005). Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology (Berl) 179: 303-309.
56. Krystal JH, D'Souza DC, Karper LP, Bennett A, Abi-Dargham A, Abi-Saab D et al (1999). Interactive effects of subanesthetic ketamine and haloperidol in healthy humans. Psychopharmacology (Berl) 145: 193-204.
57. Krystal JH, Karper LP, Bennett A, D'Souza DC, Abi-Dargham A, Morrissey K et al (1998). Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans. Psychopharmacology (Berl) 135: 213-229.
58. Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA (2001). Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 25: 455-467.
59. Lahti RA, Evans DL, Stratman NC, Figur LM (1993). Dopamine D4 versus D2 receptor selectivity of dopamine receptor antagonists: possible therapeutic implications. Eur J Pharmacol 236: 483-486.
60. Langsjo JW, Kaisti KK, Aalto S, Hinkka S, Aantaa R, Oikonen V et al (2003). Effects of subanesthetic doses of ketamine on regional cerebral blood flow, oxygen consumption, and blood volume in humans. Anesthesiology 99: 614-623.
61. Large CH (2007). Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs? J Psychopharmacol 21: 283-301.
62. Large CH, Webster EL, Goff DC (2005). The potential role of lamotrigine in schizophrenia. Psychopharmacology (Berl) 181: 415-436.
63. Linn S, Negi S, Gerum V, Javitt C (2003). Reversal of phencyclidine-induced prepulse inhibition deficits by clozapine in monkeys. Psychopharmacology V169: 234-239.
64. Littlewood CL, Jones N, O'Neil MJ, Mitchell SN, Tricklebank M, Williams MS (2006a). Mapping the central effects of ketamine in the rat using pharmacological MRI. Psychopharmacology V186: 64-81.
65. Littlewood CL, Diana C, Dixon AL, Dix SL, White CT, O'neill MJ et al (2006b). Using the BOLD MR signal to differentiate the stereoisomers of ketamine in the rat. NeuroImage 32: 1733-1746.
66. Lorrain DS, Baccei CS, Bristow LJ, Anderson JJ, Varney MA (2003). Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 117: 697-706.
67. Malhotra AK, Adler CM, Kennison SD, Elman I, Pickar D, Breier A (1997a). Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine. Biol Psychiatry 42: 664-668.
68. Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, Pickar D et al (1997b). Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 17: 141-150.
69. Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D et al (1996). NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 14: 301-307.
70. Mancini-Marie A, Stip E, Fahim C, Mensour B, Leroux JM, Beaudoin G et al (2004). Fusiform gyrus and possible impairment of the recognition of emotional expression in schizophrenia subjects with blunted affect: a fMRI preliminary report. Brain Cogn 54: 153-155.
71. Mandeville JB, Marota JJA, Kosofsky BE, Keltner JR, Weissleder R, Rosen B et al (1998). Dynamic functional imaging of relative cerebral blood volume during rat forepaw stimulation. Magn Reson Med 39: 615-624.
72. Mark JM, Laetitia S, Alain G, Didier C, Mauricette B (2004). The role of dopamine D 3 compared with D 2 receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective antagonists in rats. Psychopharmacology V174: 341-357.
73. Maurel-Remy S, Bervoets K, Millan MJ (1995). Blockade of phencyclidine-induced hyperlocomotion by clozapine and MDL 100 907 in rats reflects antagonism of 5-HT2A receptors. Eur J Pharmacol 280: R9-R11.
74. McKie S, Lees J, Hallak J, Deakin JF, Williams SCR (2007). Pretreatment by lamotrigine attenuates the ketamine-induced BOLD response in healthy volunteers: a phMRI study. Book of abstracts: 15th Annual Meeting of the International Society of Magnetic Resonance in Medicine: p 24.
75. Meibach RC, Glick SD, Cox R, Maayani S (1979). Localisation of phencyclidine-induced changes in brain energy metabolism. Nature 282: 625-626.
76. Meltzer HY (1996). Pre-clinical pharmacology of atypical antipsychotic drugs: a selective review. Br J Psychiatry Suppl 29: 23-31.
77. Messenheimer JA (1995). Lamotrigine. Epilepsia 36(Suppl 2): S87-S94.
78. Millan M (2005). N-Methyl-d-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives. Psychopharmacology 179: 30-53.
79. Mitelman SA, Shihabuddin L, Brickman AM, Hazlett EA, Buchsbaum MS (2005). Volume of the cingulate and outcome in schizophrenia. Schizophr Res 72: 91-108.
80. Miyamoto S, Leipzig JN, Lieberman JA, Duncan GE (2000). Effects of ketamine, MK-801, and amphetamine on regional brain 2-deoxyglucose uptake in freely moving mice. Neuropsychopharmacology 22: 400-412.
81. Moghaddam B, Adams BW (1998). Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281: 1349-1352.
82. Morari M, O'Connor WT, Ungerstedt U, Fuxe K (1994). Dopamine D1 and D2 receptor antagonism differentially modulates stimulation of striatal neurotransmitter levels by acid. Eur J Pharmacol 256: 23-30.
83. Morris BJ, Cochran SM, Pratt JA (2005). PCP: from pharmacology to modelling schizophrenia. Curr Opin Pharmacol 5: 101-106.
84. Mukherjee J, Christian BT, Narayanan TK, Shi B, Mantil J (2001). Evaluation of dopamine D-2 receptor occupancy by clozapine, risperidone, and haloperidol in vivo in the rodent and nonhuman primate brain using 18F-fallypride. Neuropsychopharmacology 25: 476-488.
85. Nakki R, Sharp FR, Sagar SM, Honkaniemi J (1996). Effects of phencyclidine on immediate early gene expression in the brain. J Neurosci Res 45: 13-27.
86. Neill JC, Jones DN, Hagan JJ, Thomas DR (2006). Antagonism at 5-HT7 receptors attenuates a PCP-induced reversal learning deficit in the rat. Schizophr Res 81(Suppl): 233.
87. Nordstrom AL, Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G (1995). D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 152: 1444-1449.
88. Paxinos G, Watson C (1998). The Rat Brain in Stereotactic Coordinates. Academic Press: San Diego.
89. Qiao H, Noda Y, Kamei H, Nagai T, Furukawa H, Miura H et al (2001). Clozapine, but not haloperidol, reverses social behavior deficit in mice during withdrawal from chronic phencyclidine treatment. NeuroReport 12: 11-15.
90. Risterucci C, Jeanneau K, Schoppenthau S, Bielser T, Kunnecke B, von Kienlin M et al (2005). Functional magnetic resonance imaging reveals similar brain activity changes in two different animal models of schizophrenia. Psychopharmacology (Berl) 180: 724-734.
91. Schneider F, Weiss U, Kessler C, Salloum JB, Posse S, Grodd W et al (1998). Differential amygdala activation in schizophrenia during sadness. Schizophr Res 34: 133-142.
92. Schoepp DD, Marek GJ (2002). Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia? Curr Drug Targets CNS Neurol Disord 1: 215-225.
93. Schotte A, Bonaventure P, Janssen PF, Leysen JE (1995). In vitro receptor binding and in vivo receptor occupancy in rat and guinea pig brain: risperidone compared with antipsychotics hitherto used. Jpn J Pharmacol 69: 399-412.
94. Schotte A, Janssen P, Gommeren W, Luyten W, Gompel P, Lesage A et al (1996). Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124: 57-73.
95. Schotte A, Janssen PF, Megens AA, Leysen JE (1993). Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Res 631: 191-202.
96. Schwarz AJ, Danckaert A, Reese T, Gozzi A, Paxinos G, Watson C et al (2006a). A stereotaxic MRI template set for the rat brain with tissue class distribution maps and co-registered anatomical atlas: application to pharmacological MRI. NeuroImage 32: 538-550.
97. Schwarz AJ, Reese T, Gozzi A, Bifone A (2003). Functional MRI using intravascular contrast agents: detrending of the relative cerebrovascular (rCBV) time course. Magn Reson Imaging 21: 1191-1200.
98. Schwarz AJ, Whitcher B, Gozzi A, Reese T, Bifone A (2006b). Study-level wavelet cluster analysis and data-driven signal models in pharmacological MRI. J Neurosci Methods 159: 346-360.
99. Seeman P (2002). Atypical antipsychotics: mechanism of action. Can J Psychiatry 47: 27-38.
100. Shi WX, Zhang XX (2003). Dendritic glutamate-induced bursting in the prefrontal cortex: further characterization and effects of phencyclidine. J Pharmacol Exp Ther 305: 680-687.
101. Sim K, Cullen T, Ongur D, Heckers S (2006). Testing models of thalamic dysfunction in schizophrenia using neuroimaging. J Neural Transm V113: 907-928.
102. Soyka M, Koch W, Moller HJ, Ruther T, Tatsch K (2005). Hypermetabolic pattern in frontal cortex and other brain regions in unmedicated schizophrenia patients. Results from a FDG-PET study. Eur Arch Psychiatry Clin Neurosci 255: 308-312.
103. Swanson CJ, Bures M, Johnson MP, Linden AM, Monn JA, Schoepp DD (2005). Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat Rev Drug Discov 4: 131-144.
104. Tamminga CA, Lahti AC, Medoff DR, Gao XM, Holcomb HH (2003). Evaluating glutamatergic transmission in schizophrenia. Ann NY Acad Sci 1003: 113-118.
105. Tandon R, Fleischhacker W (2005). Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment. Schizophr Res 79: 145-155.
106. Tauscher J, Hussain T, Agid O, Verhoeff NP, Wilson AA, Houle S et al (2004). Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics. Am J Psychiatry 161: 1620-1625.
107. Wadenberg ML, Kapur S, Soliman A, Jones C, Vaccarino F (2000). Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats. Psychopharmacology (Berl) 150: 422-429.
108. Weissman AD, Dam M, London ED (1987). Alterations in local cerebral glucose utilization induced by phencyclidine. Brain Res 435: 29-40.
109. Whitcher B, Schwarz AJ, Barjat H, Smart SC, Grundy RI, James MF (2005). Wavelet-based cluster analysis: data-driven grouping of voxel time courses with application to perfusion-weighted and pharmacological MRI of the rat brain. NeuroImage 24: 281-295.
110. Worsley KJ, Evans AC, Marrett S, Neelin P (1992). A three-dimensional statistical analysis for CBF activation studies in human brain. J Cereb Blood Flow Metab 12: 900-918.
111. Yamamoto BK, Cooperman MA (1994). Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J Neurosci 14: 4159-4166.
112. Yang TT, Wang SJ (2005). Effects of haloperidol and clozapine on glutamate release from nerve terminals isolated from rat prefrontal cortex. Synapse 56: 12-20.
113. Zafra F, Aragon C, Olivares L, Danbolt NC, Gimenez C, Storm-Mathisen J (1995). Glycine transporters are differentially expressed among CNS cells. J Neurosci 15: 3952-3969.